GEN Exclusives

More »

GEN News Highlights

More »
Jun 13, 2012

FivePrime Licenses BioWa, Lonza’s Cell Line for Anticancer Antibody Pipeline

  • FivePrime Therapeutics negotiated a license to use BioWa and Lonza’s Potelligent® CHOK1SV cell line as part of the R&D and production of multiple anticancer antibodies in its pipeline. The host cell line combines BioWa’s engineered glycosylation technology Potelligent with Lonza’s GS Gene Expression System, including the CHOK1SV cell line, which is used for the production of therapeutic recombinant proteins and monoclonal antibodies.

    “The combination of the clinical validation seen with other Potelligent antibodies and the track record of the GS cell line were key to our decision to select this system to enhance the potential for therapeutic efficacy of our emerging pipeline of antibodies in oncology,” comments Michael Kavanaugh, M.D., svp for research and development at FivePrime.

    BioWa and Lonza teamed up to develop the Potelligent CHOK1SV cell line back in 2007, and launched the technology in 2009. BioWa’s Potelligent platform is a method for producing 100% fucose-free monoclonal antibodies in CHO cells, by knocking out the FUT8 gene responsible for the addition of fucose to sugar chains. The technology can be applied to current antibody manufacturing processes. The firm claims knocking out fucose leads to increased Fc receptor binding, results in antibodies that demonstrate a marked increase in antibody-dependent cellular cytotoxicity, and lowers the required therapeutic dose. 

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »